Skip to main content
. 2020 Jan 3;13(3):462–472. doi: 10.1111/cts.12728

Figure 1.

Figure 1

Trial A: Mean (± SD) ubrogepant plasma concentrations in healthy participants. (a) Part 1 following administration of 100–400 mg doses in 24 hours, and (b) part 2 following administration of 40–400 mg doses once daily for 10 days. Top panel: Linear scale, bottom panel: semi‐log scale.